The launch follows a €5m investment in the company’s France based siliconisation production line
Leader in pharma glass packaging solutions SGD Pharma will exhibit its range of products and services on at CPHI Worldwide, in Milan, Italy, from 8th to 10th October 2024.
SGD Pharma will be showing its siliconised molded glass vials at CPHI. SGD Pharma’s siliconisation is an internal treatment that provides additional functionalities to a glass vial.
The internal coating provides essential protection for sensitive, aggressive and viscous drug products, reducing interaction with the packaging and preserving drug product integrity.
Siliconisation is available for all glass types in vial sizes ranging from 3ml to 500ml in both clear and amber glass. Siliconisation is suitable for all types of administration (parenteral, oral, nasal).
SGD Pharma’s €5 million investment in the siliconisation production line at its Saint-Quentin Lamotte (SQLM) plant in France enables customers to receive orders of high-performance vials at speed meeting global demand.
With the increasing demand for approval of biologics, new therapeutic approaches and the development of specialty drugs, the demand for ready-to-use (RTU) packaging continues to grow.
SGD Pharma claims to be the only supplier offering a RTU solution in molded glass, with its Sterinity EZ-fill vials designed to meet the requirements of the pharmaceutical industry, speed up time to market and reduce total cost of ownership as a result of increased quality and flexibility.
At CPHI, SGD Pharma will present an extension to its Sterinity range. By adding a RTU Type II molded glass vial for the first time.
Sterinity RTU in Type II will initially be available in size 10H with the extended range of sizes expected to be available during 2025. Sterinity Type I is currently available in sizes 10ml, 20ml, 25ml, 50ml and 100ml, in both clear and amber glass. Sterinity is suitable for various applications from veterinary to human health.
Olivier Rousseau, CEO, SGD Pharma, said: “As we support the UN Global Compact for the fifth consecutive year, we are particularly proud of our progress in reducing carbon emissions at our global glass manufacturing sites."
He continued: "SGD Pharma’s renewable energy initiatives, including the upgrade of our furnace at Saint Quentin Lamotte (SQLM) in France and the installation of solar panels at our Vemula, India plant, underscore an overarching focus on decarbonisation with the company-wide goal to cut emissions recorded in 2020, by 35% by 2030 and by 65% by 2040. These efforts reflect our responsibility to our customers, partners and the planet as we strive for a safer and healthier environment.”
